Results 131 to 140 of about 36,390 (302)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

, 2007
BACKGROUND: Non-eosinophilic asthma is a potentially important clinicopathological phenotype since there is evidence that it responds poorly to inhaled corticosteroid therapy. However, little is known about the underlying airway immunopathology and there
Shaw, DE, Brightling, C, Morgan, A, Pavord, ID, Wardlaw, AJ, Berry, M, Parker, D, Bradding, P, Green, R   +8 more
core   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

Allergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk, J. J. Otten, H. B. E. Elzinga, R. J. L. van der Lans, G. F. J. P. Adriaensen, L. B. L. Benoist, D. R. Hoven, W. J. Fokkens, S. Reitsma, PolyREG Consortium, A.B. Rinia, I. Krebbers, I.J. Kleiss, M. E. Cornet   +13 more
wiley   +1 more source

The eosinophil and airway remodelling in asthma

The Clinical Respiratory Journal, 2010
AbstractObjectives:  Eosinophils are common findings cells in allergic asthma as is sub‐base membrane thickening of the airways. The objective of this review was to summarise some recent findings linking the activities of eosinophils to airways remodelling.Data Source and Study Selection:  The study used a review of current literature with emphasis on ...
openaire   +2 more sources

Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U‐BIOPRED Cohort

Allergy, EarlyView.
No stable features were identified as associated with asthma symptom control in transcriptomics or sputum proteomics. Higher TWEAKR/TNFRSF12A and MBL/MBP‐C serum levels increased the odds of uncontrolled symptoms, while higher MK08/MAPK8 and CD5L serum levels decreased the odds, after adjustment for clinical variables.
Joana Antão, Guilherme Rodrigues, Nazanin Zounemat‐Kermani, Paolo Montuschi, Qichen Deng, Frits M. E. Franssen, Lars I. Andersson, Ian M. Adcock, Sven‐Erik Dahlén, Scott S. Wagers, Martijn A. Spruit, Alda Marques, on behalf of the U‐BIOPRED Study Group, M. I. Abdel‐Aziz, C. Auffray, Y. E. Badi, P. Bakke, A. T. Bansal, F. Baribaud, S. Bates, A. F. Behndig, E. H. Bel, J. Bigler, B. Billing, M. J. Boedigheimer, K. Bønnelykke, J. Brandsma, P. Brinkman, E. Bucchioni, D. Burg, A. Bush, M. Caruso, R. Chalekis, P. Chanez, B. Chaves, F. K. Chung, T. Checa, C. H. Compton, J. Corfield, D. Cunoosamy, A. D’Amico, B. Dahlén, B. De Meulder, R. Djukanovic, V. J. Erpenbeck, D. Erzen, K. Fichtner, L. J. Fleming, E. Formaggio, S. J. Fowler, U. Frey, M. Gahlemann, T. Geiser, V. Goss, Y. Guo, S. Hashimoto, J. Haughney, G. Hedlin, P. W. Hekking, T. Higenbottam, J. M. Hohlfeld, C. Holweg, I. Horváth, P. Howarth, A. J. James, R. G. Knowles, J. Kolmert, J. Konradsen, N. Krug, N. Lazarinis, C.‐X. Li, M. J. Loza, R. Lutter, A. Manta, S. Masefield, Maitland‐van der Zee Anke‐Hilse, J. G. Matthews, A. Mazein, R. J. M. Middelveld, M. Miralpeix, C. S. Murray, J. Musial, S. Mumby, D. Myles, B. Nordlund, H. Olsson, I. Pandis, S. Pavlidis, A. Platt, A. Postle, P. Powel, G. Praticò, M. Puig Valls, N. Rao, S. Reinke, J. Riley, A. Roberts, G. Roberts, A. Rowe, T. Sandström, W. Seibold, D. E. Shaw, R. Sigmund, F. Singer, P. J. Skipp, M. Smicker, A. R. Sousa, M. Sparreman‐Mikus, P. J. Sterk, K. Sun, B. Thornton, A. Versi, N. H. Vissing, A. M. Wheelock, C. E. Wheelock, S. J. Wilson, V. Yasinska, Aliprantis Antonios, Allen David, Alving Kjell, P. Badorrek, Balgoma David, S. Ballereau, Barber Clair, Batuwitage Manohara Kanangana, An Bautmans, A. Bedding, A. F. Behndig, Beleta Jorge, A. Berglind, Bochenek Grazyna, Braun Armin, D. Campagna, Carayannopoulos Leon, C. Casaulta, A. Chaiboonchoe, Davison Timothy, De Alba Jorge, Dekker Tamara, Delin Ingrid, P. Dennison, Dijkhuis Annemiek, Dodson Paul, Draper Aleksandra, K. Dyson, Edwards Jessica, L. El Hadjam, Emma Rosalia, Ericsson Magnus, C. Faulenbach, Flood Breda, G. Galffy, Gallart Hector, D. Garissi, J. Gent, M. Gerhardsson de Verdier, D. Gibeon, Gomez Cristina, Gove Kerry, Gozzard Neil, E. Guillmant‐Farry, E. Henriksson, Hewitt Lorraine, U. Hoda, Hu Richard, Hu Sile, X. Hu, E. Jeyasingham, K. Johnson, N. Jullian, Kamphuis Juliette, J. Kennington Erika, Kerry Dyson, G. Kerry, M. Klüglich, Knobel Hugo, J. Knox Alan, Kolmert Johan, J. R. Konradsen, Kots Maxim, Kretsos Kosmas, L. Krueger, Kuo Scott, Kupczyk Maciej, A.‐S Lantz, Larminie Christopher, L. X. Larsson, P. Latzin, N. Lazarinis, Lefaudeux Diane, N. Lemonnier, Li Chuan‐Xing, Lone‐Latif Saeeda, L. A. Lowe, Manta Alexander, Marouzet Lisa, Martin Jane, Mathon Caroline, L. McEvoy, Meah Sally, A. Menzies‐Gow, Metcalf Leanne, Meiser Andrea, Mikus Maria, Monk Philip, N. Mores, Naz Shama, K. Nething, Nicholas Ben, U. Nihlén, Nilsson Peter, R. Niven, B. Nordlund, S. Nsubuga, Pacino Antonio, Palkonen Susanna, L. Pahus, J. Pellet, Pennazza Giorgio, Petrén Anne, Pink Sandy, C. Pison, Rahman‐Amin Malayka, Ravanetti Lara, Ray Emma, Reinke Stacey, Reynolds Leanne, K. Riemann, Robberechts Martine, J. P. Rocha, C. Rossios, Russell Kirsty, Rutgers Michael, G. Santini, Santonico Marco, M. Saqi, Schoelch Corinna, S. Scott, N. Sehgal, A. Selby, Sjödin Marcus, Smids Barbara, Smith Caroline, Smith Jessica, M. Smith Katherine, P. Söderman, A. Sogbesan, F. Spycher, Staykova Doroteya, S. Stephan, J. Stokholm, K. Strandberg, M. Sunther, M. Szentkereszty, L. Tamasi, K. Tariq, Thörngren John‐Olof, Thorsen Jonathan, S. Valente, W. M. van Aalderen, M. van de Pol, C. M. van Drunen, Van Eyll Jonathan, Versnel Jenny, Vink Anton, C. von Garnier, A. Vyas, A. H. Wagener, Wald Frans, Walker Samantha, Ward Jonathan, Wetzel Kristiane, Wiegman Coen, Z. Weiszhart, Williams Siân, Yang Xian, Yeyasingham Elizabeth, W. Yu, W. Zetterquist, Z. Zolkipli, A. H. Zwinderman, Martina Gahlemann, Luigi Visintin, Hazel Evans, Martine Puhl, Lina Buzermaniene, Val Hudson, Laura Bond, Pim de Boer, Guy Widdershoven, Ralf Sigmund, David Supple, Dominique Hamerlijnck, Jenny Negus, Juliёtte Kamphuis   +294 more
wiley   +1 more source

CD11b Expression Level Measurement to Distinguish Asthma Phenotype in Pediatric Patients

Avicenna Journal of Medicine
Background Inflammation is involved in asthma pathogenesis. Based on the majority of inflammatory cells found in blood samples, asthma is divided into neutrophilic and eosinophilic phenotype.
Tien Budi Febriani, Soeroyo Mahfudz, Emi Azmi Choironi, Ninda Devita, Adika Zhulhi Arjana, Muhammad Nur Imansyah   +5 more
doaj   +1 more source

Reslizumab in eosinophilic asthma : a review

, 2017
Reslizumab (Cinqaero (R); Cinqair (R)) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation.
Guy Brusselle, Brusselle, Guy, Deeks, ED, Emma D. Deeks, Deeks, Emma D   +4 more
core   +1 more source

Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry

Introduct & imath;on: Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from ...
Çelik, Gülfem Elif, Kepil Özdemir, Seçil, Alpagat, Gülistan, Karadoğan, Dilek, Yıldız, Füsun, Gemicioğlu, Bilun, Hayme, Serhat   +6 more
core   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

Allergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy, D. Schnoegl, V. Houghton, L. O'Mahony, A. F. Santos, E. F. Knol, A. Kuehn, T. Eiwegger   +7 more
wiley   +1 more source

Advancements in biologic therapy in eosinophilic asthma

Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low is non-atopic, non-eosinophilic, and oft associated with ...
Juan Carlos Cardet (18368645), John Fowler (537703), Thomas B. Casale (13257819), Rini Patadia (18368639), Shiven Patel (18368642)   +4 more
core   +2 more sources

TNF Superfamily and ILC2 Activation in Asthma

Biomolecules
Eosinophilic asthma is the most prevalent and well-defined phenotype of asthma. Despite a majority of patients responding to corticosteroid therapy and T2 biologics, there remains a subset that have recurrent asthma exacerbations, highlighting a need for
Takahiro Matsuyama, Brittany Marie Salter, Nahal Emami Fard, Kentaro Machida, Roma Sehmi   +4 more
doaj   +1 more source